Amendment 0001.pdf

This document is an amendment to a solicitation (RFQ HT9402-24-Q-9401) for the Department of Defense (DoD) Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program. The purpose of the amendment is to update the November 2024 Pharmacy and Therapeutics (P&T) Committee meeting reporting document to add information about Oral CGRP Agents under the Migraine Agents drug class. All other terms and conditions of the original solicitation remain the same. The solicitation is for pharmaceutical agents within drug classes identified for placement on the DoD Uniform Formulary, including Migraine Agents, Targeted Immunomodulatory Biologics: Interleukin 17, and Targeted Immunomodulatory Biologics: Interleukin 23. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the P&T Committee's decisions. The RFQ provides instructions, important deadlines, and points of contact, including a pre-quote teleconference on July 24, 2024.